Shots:
- The EC has approved Vimkunya (pre-filled syringe) against CHIKV disease in individuals (≥12yrs.) in 30 EEA states; launch expected in H1’25. MAA under the UK’s MHRA review with decision anticipated in H1’25
- Approval was based on 2 P-III studies that met their 1EP of rapid immune response in 1wk. with ~97.8% of participants (n>3,500) developing neutralizing antibodies by day 21
Vimkunya is an adjuvanted VLP recombinant protein vaccine with an uncharacterized MoA
Ref: Bavarian Nordic | Image: Bavarian Nordic
Related News:- Bavarian Nordic Receives CHMP’s Positive Opinion for Vimkunya to Prevent Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
